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Abstract: Concordant with the emergence of methicillin-resistant Staphylococcus aureus 
(MRSA) in the community setting, colonization and infections with this pathogen have become a 
prevalent problem among the human immunodeficiency virus (HIV)-positive population. A variety 
of different host- and, possibly, pathogen-related factors may play a role in   explaining the increased 
prevalence and incidence observed. In this article, we review   pathophysiology,   epidemiology, 
clinical manifestations, and treatment of MRSA in the   HIV-infected population.
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Introduction
In persons infected with the human immunodeficiency virus (HIV), Staphylococcus aureus 
(S. aureus) infections account for significant morbidity.1–3 S. aureus was recognized to 
colonize the anterior nares of HIV-infected patients with greater frequency than that of 
the general population dating back to the 1990s, leading authors to postulate that this 
higher colonization burden might translate into a higher incidence of infections.4,5
Methicillin-resistant Staphylococcus aureus (MRSA) was first reported in the 1960s 
and started to establish itself as a nosocomial pathogen with increasing prevalence 
rates among hospitals nationally and worldwide.6,7 Originally associated only with 
health care-acquired infections, MRSA began to be recognized as an important cause 
of community-onset infections in the late 1990s.8–10 Now recognized as community-
acquired MRSA (CA-MRSA), the latter differs genotypically and phenotypically from 
health care–associated MRSA (HA-MRSA). CA-MRSA isolates carry much smaller 
staphylococcal cassettes (SCCmec types IV , V , or VII),11,12 have different lineages (the 
predominant lineages by multilocus sequence typing are sequence types ST80 and ST30 
outside the United States13–15 and ST8 and ST1 in the United States),16,17 and carry 
the Panton Valentine leukocidin (PVL) gene (which encodes for a S. aureus toxin that 
  creates pores on host cell membranes);13 From a clinical standpoint,   CA-MRSA isolates 
most commonly involve skin and soft tissues,16 tend to affect younger patients,18–23 and 
are characteristically susceptible to a greater number of non–β lactam antibiotics.22,24 
MRSA has thus established itself as a heterogeneous group of organisms with dif-
ferent epidemic potentials resulting in its constantly evolving epidemiology. This 
  heterogeneity is also represented by different virulence potentials and complex interac-
tions with susceptible hosts. HIV-infected patients are now recognized as one of these 
higher risk groups due to increased rates of both MRSA colonization and infections 
over the past decade. The organism’s interactions and disease manifestations with Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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the immunocompromised host are expected to be complex 
and diverse as the epidemiology of MRSA and that of HIV 
continue to change over time.
Herein, we review the pathophysiology,   epidemiology, 
clinical manifestations, and treatment of MRSA in the 
  HIV-infected population. It is important to note that   specific 
issues related to colonization and infection may vary widely 
depending on the time period of the study, specific   population 
studied, and the prevalence of antiretroviral   treatment in 
the population, and to note that most of the   available data 
are focused on CA-MRSA infections originating from 
North America where clonal group USA300 (ST8 by 
  multilocus sequence typing) predominates.
HIV and host defense against 
Staphylococcus aureus
Innate immunity represents the main host defense against 
S. aureus, with neutrophils being the primary   cellular 
defense of the innate immune response.25,26 Proper   neutrophil 
  function requires the coordination of many steps,   including 
  chemotaxis, phagocytosis, intracellular killing, and   subsequent 
  apoptosis.25 Although not as well studied as   cellular or adap-
tive immunity, the innate immune response in persons with 
HIV have revealed significant neutrophil   dysfunction that 
may increase the risk of bacterial infections.
Chemotaxis involves the active recruitment of   neutrophils 
to the site of infection and is the first step in bacterial 
  eradication. An early study evaluating neutrophil   chemotaxis 
in persons with HIV found a more than 45% reduction 
in chemotaxis in persons with AIDS-related complex vs 
healthy controls. In addition, the serum from persons with 
HIV inhibited chemotaxis in neutrophils from the controls,27 
suggesting that a serum molecule may be responsible for 
decreased chemotaxis in persons with HIV . In a subsequent 
study, the chemotactic index of neutrophils in children with 
asymptomatic HIV infection was 29.8% lower than that in 
healthy controls.28 In these studies, decreased chemotaxis 
was predominantly seen in persons with early HIV disease. 
One possible explanation is that increased cytokine expres-
sion in late-stage HIV may increase random neutrophil 
migration.28 In contrast to the more pronounced chemotaxis 
inhibition in early HIV disease described above, a   longitudinal 
evaluation of neutrophil function in untreated HIV patients 
found an initial 19% decrease in chemotaxis that progressed 
to a 32% decrease after 3 years of   follow-up.29 In addition, 
the dysregulation of L-selectin expression (an adhesion mol-
ecule important in neutrophil binding to the endothelium) 
has been shown to increase with   decreasing CD4 counts.30 
Although data are limited, highly active antiretroviral 
treatment (HAART) may improve neutrophil chemotactic 
function. In a cohort of 18 HIV-infected persons with CD4 
T-cell counts , 350/µL and diminished baseline neutrophil 
chemotaxis, chemotactic activity was found to be in the 
normal range in 72% after 9 months on HAART.31
After chemotaxis, neutrophil phagocytosis and intracel-
lular killing are vital steps in host defense against S. aureus.25 
Several studies have found decreased neutrophil phagocytosis 
of S. aureus in HIV-infected patients compared with healthy 
controls.32 Studies demonstrating reduced bacterial phagocy-
tosis and respiratory burst with decreasing CD4 counts and a 
significantly increased capacity of   neutrophils to phagocytose 
S. aureus in early HIV suggest that phagocytosis may depend 
on the stage of HIV infection.33,34 Paradoxically, no difference 
was found in the phagocytosis of S. aureus in asymptomatic 
and symptomatic HIV-infected patients vs controls, but 
phagocytosis by normal neutrophils was less efficient when 
bacteria were preopsonized with serum from HIV-infected 
persons, implying that defective opsonization may exist in 
HIV-infected persons.28 Studies have also shown a reduced 
bactericidal capacity of neutrophils in HIV-infected persons. 
A .20% decrease in the intracellular killing of S. aureus 
was found in neutrophils from HIV-infected patients vs 
healthy controls.35 In contrast to studies that show impaired 
phagocytic oxidative capacity in HIV-infected patients may 
be explained by reduced intracellular bacterial killing,35–37 the 
impaired bactericidal capacity in this study was not explained 
by a defect in the production of reactive oxygen species.36 
As is true for the defects in chemotaxis and phagocytosis, 
there is evidence that this decreased bactericidal activity 
of neutrophils against S. aureus in HIV-infected patients is 
more pronounced with late-stage HIV disease,27,28 and that 
bacterial killing by neutrophils from healthy controls can be 
decreased when S. aureus is pretreated with the serum of HIV 
patient, again revealing a possible defect of opsonization in 
patients with HIV .27,28 The effect of HAART on neutrophil 
bactericidal function is still unclear.
Neutropenia is a well-recognized consequence of HIV 
infection and increases the risk of bacterial infections.38 
The etiology of neutropenia in HIV-infected persons is 
multifactorial with bone marrow invasion by   opportunistic 
infections, treatment-related hematologic toxicities, and 
nutritional deficiency, all potentially playing a role.38 
Another mechanism may be increased neutrophil apoptosis, 
which has been shown to be accelerated in HIV-infected 
persons.39–41 Pitrak et al40 found that neutrophil viabil-
ity in culture was markedly decreased after 18 hours in Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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patients with AIDS (58.8%) vs healthy controls (83.5%).40 
It is believed the oxidative stress of HIV may, in part, be 
responsible for accelerated neutrophil death.41 Protease 
inhibitors (PIs) have been shown in vitro to inhibit neu-
trophil apoptosis,42 thus suggesting PI use may potentially 
reverse some of the accelerated neutrophil apoptosis seen 
in HIV-infected persons.
Many other cells play an important role in host defense 
against S. aureus, including monocytes and B lymphocytes. 
Monocytes are involved in the phagocytosis of bacteria, 
the production of immunomodulating cytokines (many of 
which direct and organize neutrophil function), and the 
removal of apoptotic neutrophils. Studies have shown 
significant monocyte dysfunction exists in HIV-infected 
patients.32,33,43 Moreover, the HIV Nef protein has been 
found to decrease monocyte chemotaxis and to inhibit the 
phagocytosis of apoptotic neutrophils, thus potentially 
contributing to an increased inflammatory state in HIV-
infected persons.44,45
Finally, B lymphocytes produce antibodies that are an 
essential component of antibacterial immune responses and 
increase the efficiency of neutrophil phagocytosis. Since 
early on in the HIV epidemic, B-cell abnormalities and the 
production of dysfunctional antibodies have been recognized 
in HIV-infected persons and believed to increase the risk of 
bacterial infections.46,47
The demonstrated defects in innate immunity surely 
contribute to the high rates of S. aureus infections in per-
sons infected with HIV . Further work is needed to evaluate 
Table 1 Prevalence of MRSA colonization in HIv-positive patients
Patient  
population
No. of  
HIV-infected 
patients
Median CD4 count  
of the cohort
HIV patients colonized 
with S. aureus, %
HIV patients colonized  
with MRSA, %
Reference
Outpatienta 100 450 49 2 157
Outpatientb 243 NA NA 3.8 58
Outpatientc 100 NA NA 2 158
Outpatientc 146 328 NA 10.3 59
Outpatientc 158 NA 27 4 65
Outpatientc 163 NA 21.5 3.1 159
Outpatientc 195 270 23 3 160
Outpatientc 111 NA 64.6d 0 55
Outpatientc 900 NA NA 8 79
In/outpatientc 178 NA NA 34.8 161
Outpatient 162 205 30 6 51
Outpatiente 60 NA 76.7 17.4 162
Outpatientf 107 612 58.9d 16.8d 54
Inpatient 81 NA NA 17 48
Inpatientg 239 NA NA 31.4 53
Notes: aID clinic; bClinic for gay, lesbian and transgender patients; cHIv clinic; dCumulative prevalence; ePatients with HIv infection attending a dermatology clinic; fMSM; 
gChildren admitted to a hospital in South Africa with pneumonia. 
Abbreviations: MRSA, Methicillin-resistant Staphylococcus aureus; HIV, human immunodeficiency virus; NA, not available; ER, emergency room. 
the effect of HAART on the recovery of the innate immune 
response against S. aureus.
Epidemiology and clinical 
manifestations
Colonization
The prevalence of colonization with S. aureus varies   according 
to the population studied. Groups of patients with higher colo-
nization rates have been identified, including patients with HIV 
infection.48–55 For MRSA, specifically, colonization rates of 
0%–17% have been reported for   HIV-positive outpatients and 
17%–31% for inpatients (Table 1). HIV has been identified as 
an independent risk factor for determining colonization with 
MRSA.48,49,52,56 The reason for the higher colonization rates 
observed are unclear, but could include   factors such as frequent 
contact with both health care and community settings and 
frequent exposure to antibiotics, leading to a greater likelihood 
of becoming colonized with resistant strains. Some authors 
argue that this increased   susceptibility to colonization with S. 
aureus could be HIV-specific.57 Some of the risk factors for 
colonization among HIV-infected patients suggest immunologic 
and virologic control, as well as the use of prophylactic Bactrim 
might be important   protective measures.51,52,58,59 However, 
higher colonization burdens have been shown for HIV-infected 
patients without evidence of immunosuppression, suggesting 
this association might be independent of CD4 T-lymphocyte 
counts.54 In addition, sociodemographic and behavioral fac-
tors might also play an important role in establishing higher 
colonization rates among this patient population. Table 2 Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
76
Hidron et al
summarizes independent risk factors that have been identified 
for   colonization with MRSA in HIV-positive patients.
Not all studies have found HIV status as an   independent 
risk factor for colonization.60 Potential reasons to explain 
disagreement between studies include the presence of 
other unrecognized sites of colonization (patients might 
be colonized in the genital or perineal areas but not in the 
nasopharynx),61 and intermittent colonization. The intermit-
tent nature of colonization is illustrated in the study by Shet 
et al,54 where the prevalence of MRSA colonization was 
4.7% at the first visit, 8.7% at the second visit, and 11.8% at 
the third visit for a cumulative prevalence of 16.8%.54 It has 
been estimated that up to 20% of true carriers can be missed 
when a single sample is obtained.55 As far as persistence of 
colonization in HIV-infected patients who are known to be 
colonized, 38%–39% of patients have been reported to be 
persistent carriers, but up to 62% of patients will have a 
positive S. aureus nares culture if screened at three different 
points in time.55
Whether colonization with MRSA precedes MRSA 
infection is controversial.62 Earlier to widespread reports 
of CA-MRSA, a prospective, multicenter study found that 
HIV-infected patients colonized with S. aureus were more 
likely to become infected.63 In a study looking at patients not 
known to be HIV-infected with bacteremia, blood isolates 
matched nasal isolates in 82% of patients.64 Among HIV-
infected patients, the study by Szumowski et al58 suggests an 
association between perianal MRSA colonization and skin 
and soft tissue infections (SSTIs). Pulsed-field gel electro-
phoresis (PFGE) profiles for infecting and colonizing strains 
in a recent study showed identical macrorestriction profiles.54 
Furthermore, colonization with S. aureus has been identified 
as an independent risk factor for S. aureus infections in HIV-
positive patients.54,63
In contrast, some published studies refute the role of 
prior colonization as necessary for MRSA infection. A point 
  prevalence survey done in an HIV clinic reported that only 
1 of 6 patients who had a MRSA SSTI during the previous 
6 months was colonized with MRSA.65 In this study, coloni-
zation at the time of infection was not assessed, so the absence 
of a temporal association is not certain. Similarly, in the case 
of MRSA bacteremia in HIV-infected children, S. aureus car-
riers did not have higher rates of S. aureus bacteremia than 
did noncarriers.53 Some authors have therefore suggested 
that high-risk sexual behavior may be a more important risk 
factor for transmission than actual colonization.66
Infections
Rates of MRSA infections have increased over time among 
HIV-positive patients66–70 and have been reported to be 
6-fold to 18-fold higher than in the general population.70,71 
The proportion of MRSA relative to methicilin-susceptible 
S. aureus (MSSA) infections has also increased over the last 
several years among HIV-infected children and young adults 
(from 17% to 100% of all S. aureus infections at the end of 
an 8-year follow-up period).72 In retrospective reviews, 7% 
of outpatient HIV cohorts developed CA-MRSA infections 
over prolonged follow-up (8–13 years).69,70 Similarly, in an 
asymptomatic cohort of HIV outpatients followed over a 
year, 9% developed MRSA infections in contrast to 0% of the 
uninfected controls.54 In a dermatology practice over 3 years, 
51% of CA-MRSA SSTIs were in HIV-positive patients.73 
For SSTIs, specifically, the incidence of CA-MRSA among 
  HIV-infected patients was reported to have significantly 
increased from 2000 to 2007 with USA300 MRSA account-
ing for 86% of the isolates.71 Not only HIV-positive patients 
are more likely to have community-onset S. aureus infections 
but also are more likely to have a nosocomial infection caused 
by S. aureus than HIV-negative patients.74
Whether HIV-infected patients are at increased risk of 
infections because of higher colonization rates or due to other 
social, environmental, behavioral, biologic, HIV host-specific 
risk factors, or a combination of all these is still unclear. Risk 
factors for MRSA infections have been more extensively 
studied for SSTIs in HIV-infected patients. Some authors 
Table 2 Risk factors for colonization with MRSA in HIv-positive 
patientsa
Risk factors for colonization with  
MRSA in HIV-positive patients  
(reference)
Studies that have  
found no association   
(reference)
High HIv viral load58 54,159
Low CD4 T-cell count51,52,58,59,79 54,55,159,160
Bactrim use (protective)58,59 160b
Antibiotic use (other than  
Bactrim)3,51,52,54,79,160
Hospitalization3,160
Central venous catheter3
Dermatologic disease3
No significant association found for the following risk factors 
(reference)
Intravenous drug abuse (IvDU)/recreational drug use54,159
ARv treatment status54
Prior MRSA infections54
Use of sports/gym facilities/shared towels54
Notes: aDoes  not  take  into  account  whether  isolates  are  community-acquired 
MRSA  (CA-MRSA)  vs  hospital-acquired  MRSA  (HA-MRSA);  bUse  associated  to 
risk, likely because their outpatient strain was identical to their hospital strain and 
therefore strain was likely a HA-MRSA strain.
Abbreviations:  MRSA,  Methicillin-resistant  Staphylococcus  aureus;  HIv,  human 
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postulate that CA-MRSA SSTIs are more tightly related 
with sexual behavior or drug-using behavior than they are 
with HIV .75,76 Evidence supporting the   association with high-
risk sexual practices includes a higher incidence of these 
infections in men who have sex with men (MSM),77 their 
distribution predominantly in the genital or perianal areas,70,75 
the association with a history of other sexually transmitted 
diseases,70,75 and the protective use of condoms.75 It has also 
been suggested that the colonization patterns in CA-MRSA 
infection are different from those in non-CA-MRSA infec-
tions.78 This could offer a plausible explanation to the higher 
frequency of SSTI observed in this patient population, assum-
ing a direct relationship with high-risk sexual practices.
Whether the risk for SSTI is increased among HIV 
patients with lower CD4 T-cell counts is debated: some 
studies have found a significant association,66,69,70,79 whereas 
others have not.58,75 Overall, reported mean CD4 counts at 
the time of presentation with SSTIs specifically have been 
well above 200 cells/mm3 (mean CD4 counts: 457,68 445,69 
56072). However, in favor of the role of immunosuppression, 
outbreaks have been reported in patients with extremely 
low CD4 counts (CD4 T-cell count , 10 in 66%),80 and 
85% of S. aureus infections have been reported to occur 
in patients with CD4 counts less than 100 cells/mm3 with 
this risk increasing over time.63
As would be expected, an elevated HIV viral load has 
been identified as a risk factor not only for infection66 but also 
for recurrence.69,81 Of course, patients with higher degrees 
of immunosuppression are more likely to be in contact with 
the health care system, or, alternatively, immunosuppres-
sion might represent a marker for other associated condi-
tions or behaviors. However, both low CD4 counts66,70,79,82 
and elevated HIV viral load66,69,70 have been found to be 
independent risk factors for MRSA infections. Other risk 
factors for MRSA infections in HIV-positive patients are 
listed on Table 3.
SSTI
Mirroring what is observed in the general population,3,58,66,72,75,76 
most MRSA infections in HIV-positive patients represent 
SSTI, which account for up to 83%–90% of the MRSA 
infections observed in HIV outpatients,58,66,70 and 30%–45% 
in inpatients.3,82 Likewise, the etiology of SSTI in HIV-
infected patients has been documented to be MRSA in 
37%–93% of patients;68,70,83 the vast majority of these 
are due to   CA-MRSA.70 In fact, the presence of a SSTI 
  predicts   infection with a specific clone identified by PFGE, 
the USA300 clone.79 The most common type of SSTIs are 
abscesses followed by cellulitis, furunculosis, impetigo, 
folliculitis, and carbuncles.70,75 Contrary to what would 
be expected, the majority of patients with MRSA SSTIs 
(specifically with CA-MRSA SSTIs) do not seem to have 
immunologic or virologic parameters consistent with AIDS 
at the time of infection.84 The location of SSTIs has been 
reported to be the lower extremity in 21%–32%, buttocks/
scrotum/anogenital region in 26%–40%, upper extremity in 
10%–20%, face in 3%–13%, and trunk in 3%–10%.69,70,75 
Infections usually resolve with treatment68 and are rarely 
complicated by pneumonia or osteomyelitis.72 Bacteremia 
is also an infrequent complication but has been reported in 
0%–7% of patients.68,70,72 The rates of patients requiring hos-
pitalization are similar to those of the general population.70 In 
contrast, recurrence of infection is quite common (10%–71%), 
which in some cases has been reported to occur at twice the 
rate of the general population.70 Recurrence usually occurs 
at a median of 4–4.5 months,68–70,72,76,81 and does not seem to 
be related to initial antibiotic susceptibility and antibiotics 
received for the initial SSTI;81 more frequently, recurrences 
happen at a different site of the original infection.72 Risk 
factors for recurrence include lower CD4 cell counts, higher 
HIV RNA levels, lack of incision and drainage at the time of 
initial MRSA infection,69 whereas risk factors for infection 
(specifically with a CA-MRSA isolate) include residence in 
alternative housing (ie, shelters), residence in high-risk zip 
codes, and younger age.71
Table 3 Risk factors for MRSA infections in HIv-positive patients
Risk factors for MRSA infections  
in HIV-positive patients  
(reference)
Studies that have found   
no association  
(reference)
Low CD4 count66,70,79,82 75
elevated HIv viral load66,69,70
Recent use of β-lactam antibiotics70  
or antibiotic use3,79
History of syphilis70
Bactrim use (protective)66,70,75 69a
Injection drug use, type of sexual  
practice (MSM), or both66
82
Sex partners with skin infections75
Use of a condom (protective)75
Methamphetamine use75
Use of a public hot tub or sauna75
Routine hands on contact with  
customers at work75
Cumulative hospital stay3,82
Invasive procedures in the previous year82
Central venous catheter3
Dermatologic disease3
Note: an = 1. 
Abbreviations:  MRSA,  Methicillin-resistant  Staphylococcus  aureus;  HIv,  human 
immunodeficiency virus; MSM, men who have sex with men.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Although the majority of reported SSTIs in HIV-infected 
patients are due to CA-MRSA, there are limited data with 
specific isolate typing or looking at the role of staphylococcal 
toxins that are known to be commonly associated with these 
isolates, such as PVL.85 Of the few studies for which typing is 
available, Skiest et al68 found 88% and 100% of MRSA isolates 
carried SCCmec type IV and PVL, respectively; Graber et al 
found 87% of all MRSA isolates were USA300 (which 
usually carries SCCmec type IV and PVL);17,81 and Ramsetty 
et al found that 89% of the MRSA isolates causing both 
infection and colonization in HIV outpatients were USA300.79 
Srinivasan et al72 reported a lower prevalence of infections 
with the USA300 MRSA isolate (52% PVL positive, 
USA300) among 31 HIV-infected children and young adults 
with MRSA infections, 87% of which were SSTIs. Only 
this last study attempted to determine whether PVL-positive 
MRSA strains caused increased morbidity in the HIV-positive 
population compared with PVL-negative MRSA strains. 
In addition to finding that the proportion of patients with 
PVL-positive MRSA infections did not increase over time 
(despite the fact the proportion of overall MRSA infections 
did relative to MSSA), they found that PVL-positive MRSA 
infections were significantly associated with more SSTI but 
not with increased morbidity or a higher risk of complications 
compared with PVL-negative MRSA infection.72
Invasive infections
Cases of S. aureus or MRSA necrotizing cellulitis, 
pyomyositis,86 necrotizing fasciitis,87,88 pneumonia,2,3,89 
bacteremia,3 endocarditis,63,88,90 purulent pericarditis with car-
diac tamponade,91 and even perinephric abscess2 have all been 
reported in HIV-positive patients. With few exceptions,63,82 
invasive infections (ie, bacteremia, endocarditis, pneumo-
nia, etc) are not as common as SSTIs, usually accounting 
for ,20% of MRSA infections overall.3,66,70,72 Bacteremias 
have been reported to account for approximately 10%–41% 
of MRSA infections, pneumonias for 6%–30%, and deep 
soft tissue infections, endocarditis, and other invasive 
infections accounting for even lower percentages, but these 
numbers vary depending on the type of cohort (inpatient 
vs outpatient).66,82 Regardless, these deep-seated infections 
can be a significant cause of morbidity and mortality in this 
patient population. For HIV-positive patients with S. aureus 
bacteremia, for example, mortality rates of up to 67% have 
been reported and patients are twice as likely to die compared 
with HIV-positive patients without this invasive infection.63 
The outbreak reported by Smith et al,15 additionally suggested 
that this increased morbidity and mortality might be related 
to immunosuppression because all cases occurred among 
patients with low CD4 counts (67% with CD4 counts , 10) 
and 83% had invasive disease (3 of 6 patients with bacteremia 
and 2 of 6 with pneumonia). In contrast, despite finding a 
two fold increased mortality rate in HIV-positive patients 
with an MRSA infection compared with other HIV-positive 
inpatients, a study from Italy did not find this to be a statisti-
cally significant mortality difference.82
Whether improved HIV control will result in reduced risk 
of MRSA infections and/or recurrences is argued by some69 
but remains to be proved in future studies.
Bacteremia
S. aureus is the most frequent cause of both community and 
hospital-acquired bacteremia in HIV-positive patients,2,92–94 
and MRSA can explain 32%–67% of cases of S. aureus 
bacteremia in this patient population.2,67,82,95–97 At large urban 
centers, the prevalence of HIV among patients with MRSA 
bacteremia can be up to 22%.98 Prior to the widespread 
emergence of MRSA in the community, the incidence of 
MRSA bacteremia in HIV-positive patients was thought to 
be declining.95 Burkey et al67 reported an increasing inci-
dence just a few years later. This recent increasing incidence 
temporally coincides with increasing reports of MRSA from 
the community.
After SSTIs, bacteremia is the most frequently observed 
infection among HIV-infected patients. Along with 
IVDA,67 end-stage renal disease,67 low CD4 T-cell count 
(,200 cells/µL),67,95 use of β-lactam antibiotics,95 and previ-
ous hospital admissions,95 HIV infection has been   identified 
as an independent risk factor for MRSA bacteremia.99 Hos-
pitalized patients with HIV have been reported to be almost 
17 times more likely to have S. aureus bacteremia compared 
with HIV-negative patients.96
The source of bacteremia varies depending on the time 
the study was conducted and the patient population, perhaps 
in addition to other factors. In the pre-HAART era, cases 
of S. aureus bacteremia were more frequently community-
acquired, reported among intravenous (IV) drug users, and 
commonly associated with endocarditis.2 In more recent 
studies (coinciding with widespread reports of CA-MRSA), 
the source for S. aureus bacteremia was somewhat different: 
SSTI in 15%–31% of cases, a catheter in 17%–54% of cases, 
use of IV drugs (or endocarditis) in 3%–49%, and unknown in 
approximately 19%.96,97 Significant immunosuppression can 
be observed among patients with bacteremia, with mean CD4 
counts at the time of bacteremia of 52–130 cells/mm3 and 
94% of the patients being categorized as AIDS in one of the Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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studies.96,97 Paradoxically, CD4 counts and viral loads have 
not been shown to be independent predictors for poor out-
comes. In fact, the absence of HAART has been associated 
with a lower mortality.97 Whether outcomes of HIV-infected 
patients with S. aureus bacteremia are influenced by the iso-
late’s resistance profile (MRSA vs MSSA) is another matter 
of debate: 2 studies suggest this is not the case,96,97 but a recent 
study suggests both HIV infection and methicillin resistance 
can increase at least the odds of S. aureus bacteremia recur-
rence by almost 5 and 2 times, respectively.100 Rates of 
objective outcomes, such as mortality, have not been found 
to be significantly higher in HIV-infected patients compared 
with HIV-negative patients with S. aureus bacteremia.101 In 
HIV-infected patients with S. aureus bacteremia, overall 
mortality rates are 10%–67%, and approximately 40% for 
MRSA specifically.58,63,97,101
From a clinical standpoint, little data are available 
differentiating the clinical presentations of bacteremia in 
HIV-infected and uninfected patients. Mean duration of fever, 
percentage of bands, neutrophils, and number of platelets 
are similar between HIV-infected and uninfected patients 
with S. aureus bacteremia, but HIV-infected patients do have 
significantly lower white blood cell counts on admission.96 
Complications of bacteremia may include metastatic seeding, 
pneumonia, endocarditis (which can be observed in up to 
20% of patients), relapse or recurrence of infection (observed 
in up to 17% of patients), sepsis, shock, and overall can be 
observed in approximately 13% of patients.96,97
endocarditis
The most common etiologic agent of endocarditis among 
HIV-infected patients, whether IV drug users or not, is 
S. aureus.90,102,103 The incidence, epidemiology, clinical pre-
sentation, and outcomes of infective endocarditis (IE) were 
evaluated in HIV-infected outpatients followed at one center. 
Though the study was not limited to cases with S. aureus, 
it was by far the most common etiologic organism repre-
senting 69% of the cases; of these, 28% were methicillin-
resistant. The incidence of IE in HIV-infected patients was 
found to be significantly higher than that of the general 
population. The majority of cases occurred among male, 
African-American IV drug users in their 40 years of age with 
median CD4 counts of 68 cells/mm3. These demographics 
did not differ from HIV-infected controls without IE except 
for the following identified risk factors: IV drug use, CD4 
count , 50 cells/mm3, and HIV RNA . 100,000 copies/mL.90 
Fever, chills, shortness of breath, and myalgias were the most 
common presenting symptoms. Over 50% of the patients 
in this cohort had died at 1 year, but the type of organism 
was not found to be an independent predictor of mortality. 
At 1 year, 16% of patients had recurrences, and 66% of the 
recurrences were due to S. aureus.90
A second study looking at 133 cases of S. aureus 
  endocarditis (of whom 38% were HIV-positive drug 
  abusers) from one center over a 22-year period found that 
HIV-negative patients with S. aureus IE were more likely 
to have dyspnea, cutaneous signs, neurologic lesions, 
and even a higher mortality. This can be explained by 
the fact that HIV-positive patients were more likely to 
be drug abusers and therefore to have right rather than 
left-sided endocarditis, which is associated with a more 
favorable prognosis.104 Of note, only 6% of the isolates 
were   methicillin-resistant. Reports of IE caused by CA 
phenotype isolates (ie, USA300) among HIV-positive 
patients are still limited.105
Pneumonia
As is the case for the general population, MRSA pneumonia 
among HIV-positive patients can be health-care associ-
ated, secondary to bacteremia, or community-acquired. 
MRSA is a common pathogen for nosocomial pneumonia 
in   HIV-positive patients (25% of cases due to S. aureus, 
65% of these methicillin-resistant) and has been identified 
as an independent risk factor for mortality among HIV-
positive patients.106 CA-MRSA pneumonia has been rec-
ognized as an emerging entity concurrent to the emergence 
of CA-MRSA, presenting usually after a viral prodrome 
with varying degrees of lung necrosis which manifest as 
shortness of breath, sepsis, and hemoptysis.107 It was ini-
tially recognized mainly among healthy patients,107 but in 
more recent reports, nearly 50% of the cases were among 
immunocompromised patients and 43% of the patients in 
this group were   HIV-positive.89
Necrotizing fasciitis
Overall, S. aureus was an infrequent cause of necrotizing 
fasciitis but is now recognized as an emerging clinical 
syndrome.88 Of 19 cases of CA-MRSA necrotizing   fasciitis 
reported in the literature, only 11% were HIV-positive 
patients.87 Data on the incidence and prevalence of this 
entity among HIV-positive patients are therefore limited to 
very few case reports, which impedes conclusions on com-
parative severity and clinical presentations.87,88 However, in 
general, it has been suggested that necrotizing fasciitis caused 
by   CA-MRSA may be less virulent than similar infections 
caused by other organisms.88Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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HIV and treatment of MRSA
Little data suggest that the treatment of MRSA infections in 
HIV-infected patients should be any different than the treat-
ment in noninfected patients. Below, we briefly review the 
limited data about treatment of these infections.
Treatment of MRSA SSTIs
A recent study in HIV-positive patients suggests that the anti-
biograms of MRSA isolates are showing lower susceptibility 
rates to antibiotics, such as clindamycin, erythromycin, and 
ciprofloxacin, to which MRSA isolates have classically been 
susceptible.54 Concordant with this, a study looking at the 
MSM population in Boston and San Francisco found a high 
rate of resistance to clindamycin, tetracycline, and   mupirocin 
among MRSA isolates independent of HIV infection.77 
A similar study in MSM from New York reported a high 
rate of resistance to tetracycline (23%), clindamycin (63%), 
and erythromycin (93%) in CA-MRSA isolates.108 In fact, 
recurrent infections with MRSA have been associated with 
resistance among initially susceptible isolates in MSM77 and 
in HIV-infected patients.69
A number of oral agents such as trimethoprim-
  sulfamethoxazole (TMP-SMZ), clindamycin, tetracyclines 
such as doxycycline, rifampin (in combination with other 
agents), and linezolid have been used to treat MRSA-
associated SSTIs in HIV and non-HIV patients. Despite the 
extensive use of the above-mentioned agents, there are no 
prospective controlled trials of most of these drugs prescribed 
to treat MRSA SSTIs. Small areas of skin infection with a 
drainable focus are usually cured by incision and drainage 
alone in adults17 and children.109,110 However, reported suc-
cess to therapy has been 95% of patients with CA- MRSA 
SSTI who received an active antibiotic compared with 87% in 
those who did not.111 Large lesions, associated cellulitis, and 
presence of systemic symptoms like fever may warrant the 
use of a systemic antibiotic17,112 despite the lack of supporting 
evidence from prospective controlled trials.113 Addition of 
systemic antibiotics has also been advocated with advanced 
immunodeficiency.114
TMP-SMZ remains one of the most common drugs 
used to treat uncomplicated SSTIs due to MRSA despite 
the paucity of randomized, controlled trials that support its 
efficacy in such infections. TMP-SMZ was found to have 
a greater bactericidal activity against MRSA in vitro than 
linezolid, rifampicin, minocycline, and clindamycin115 and 
was considered as an acceptable alternative to vancomycin 
for the treatment of systemic MRSA infections by Markowitz 
et al.116 Increased rates of clinical response in SSTIs have 
been reported with the use of TMP-SMZ.117 Clinicians should 
be aware that TMP-SMZ resistance among MRSA isolates 
in HIV-infected patients has been reported.50,118 The use of 
prophylactic TMP-SMZ may select for this resistance50,118,119 
although resistance has also been reported without a history 
of prior TMP-SMZ use.70 Fortunately, overall TMP-SMZ 
resistance in HIV-infected patients remains infrequent.77
Clindamycin can potentially inhibit toxin production 
i  ncluding PVL120,121 and is used to treat MRSA infections.122 
Inducible clindamycin resistance has to be ruled out by 
performing a D-test because a number of isolates that are 
  erythromycin-resistant have shown to be clindamycin-resistant 
despite appearing initially susceptible.123 The incidence of 
clindamycin resistance in the United States varies. In a study of 
SSTIs in HIV-infected patients in Dallas, 10% of CA-MRSA 
isolates were resistant to clindamycin.68 Srinivasan et al72 
reported a 19% incidence of clindamycin resistance in MRSA 
isolates from children and young adults with HIV infection at 
St. Jude Children’s Research Hospital. A study of CA-MRSA 
SSTIs in MSM in New York has found that 63% of the isolates 
were resistant to clindamycin.108 Moreover, a more recent study 
of SSTIs in otherwise healthy HIV-positive patients in New 
York found that 42.9% of all MRSA isolates were resistant to 
clindamycin.54 Given the possible increasing rate of resistance 
of MRSA isolates, clindamycin should be used with caution 
if local antibiograms suggest local high-grade resistance of 
MRSA isolates.
Long-acting tetracyclines have been used to treat MRSA-
associated infections. Clinical cure was achieved in 83% 
of patients with tetracycline-susceptible MRSA infections 
in a study by Ruhe et al.124 The same study found a similar 
response rate after review of the literature of 85 patients.124 
Importantly, recent studies have found increasing resistance 
to tetracyclines among MRSA USA300 isolates in Boston 
and San Francisco.125,126
Linezolid is a bacteriostatic agent that can be given orally 
to treat MRSA SSTIs and is approved for that indication. 
One study found that linezolid was equivalent to vanco-
mycin in treating complicated SSTIs.127 In a randomized 
trial treating diabetic foot infections, linezolid was at least 
as effective as aminopenicillin/β-lactamase inhibitors.128 
Resistance to linezolid has been reported, but it has not 
been a clinically significant problem to date.129 Linezolid, 
like clindamycin, can inhibit toxin production by MRSA 
isolates that may be helpful in the case of severe SSTIs.120 
Linezolid use has been associated with myelosuppression, 
including thrombocytopenia and anemia, which are often 
reversible after drug discontinuation.130 Neurotoxicity, mainly Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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peripheral and ocular neuropathy, has also been reported in 
patients receiving linezolid for more than 28 days.130–132
Finally, rifampin is sometimes used in combination 
with other agents although one study found the addition of 
rifampin to TMP-SMZ to be antagonistic.115
Treatment of invasive infections
Available parenteral agents for treatment of invasive MRSA 
infections, such as bacteremia, pneumonia and complicated 
SSTIs, include vancomyin, linezolid, daptomycin, tigecy-
cline, and quinupristin-dalfopristin in HIV and non-HIV 
patients. Vancomycin has been the agent of choice for treat-
ing invasive MRSA infections for years. However, resistance 
among some MRSA isolates and poor tissue penetration 
of vancomycin have raised recent concern when treating 
severe MRSA infections.133–136 Moreover, there have been 
reports of treatment failure due to heteroresistant MRSA, 
in which a subpopulation of MRSA would have a high MIC 
and reduce susceptibility to vancomycin.137 In addition, 
there is a correlation between vancomycin minimum inhibi-
tory   concentrations (MICs) and treatment outcomes.138,139 
Patients with MRSA bacteremia in one study had better 
outcomes when the isolates MIC was 0.5 µg/mL compared 
with those with 1–2 µg/mL.138
Linezolid can be administered either orally or IV to 
patients with MRSA infections. In a randomized open-label 
trial of patients with presumed MRSA infections including 
SSTIs and pneumonia, the clinical cure rates were 73.2% 
and 73.1% in the linezolid group and the vancomycin 
group, respectively.140 Despite this, whether linezolid may 
be superior to vancomycin in the treatment of MRSA 
pneumonia is still controversial, and the optimal treatment 
of nosocomial and CA-MRSA pneumonia is not clearly 
defined due to the lack of prospective trials.141 Linezolid 
is not FDA approved for treatment of MRSA bacteremia 
or endocarditis. It has been used in such cases with some 
reports of success140,142 or failure,143,144 and its efficacy in 
treatment of MRSA bacteremia or endocarditis has yet to 
be established.
Daptomycin is a bactericidal drug that is FDA approved 
for treatment of S. aureus, including MRSA SSTI bacter-
emia, and right-sided endocarditis. Daptomycin had similar 
efficacy to vancomycin in treatment of patients with com-
plicated SSTIs due to MRSA.145 In a randomized trial by 
Fowler et al146 in patients with S. aureus bacteremia with or 
without endocarditis, daptomycin was not inferior to standard 
therapy consisting of initial low-dose gentamicin with either 
antistaphylococcal penicillin or vancomycin. Importantly, 
S. aureus isolates with heteroresistance to vancomycin may 
exhibit daptomycin nonsusceptibility despite the lack of 
previous exposure to daptomycin.147 Daptomycin should not 
be used for the treatment of MRSA pneumonia because the 
drug is inactivated by pulmonary surfactant causing clinical 
failures.148 Of note, daptomycin use has been associated with 
elevated creatine kinase, myopathy, and even   rhabdomyolysis 
in some cases.146,149
Tigecycline is available as an IV drug for treatment of 
SSTIs, including MRSA SSTIs, and has been shown to be 
noninferior to vancomycin in some studies.150,151 However, its 
use has been limited, and the number of patients of MRSA 
infections receiving tigecycline has been small. In addition, 
cases of tigecycline-induced pancreatitis have been reported 
in the literature.152,153 Quinupristin-dalfopristin has been used 
for salvage therapy in MRSA infections in patients who are 
intolerant or failing standard therapy,154,155 but its use may be 
limited by the frequent adverse events, such as arthralgias 
and myalgias.156
In summary, several agents are available for treatment 
of SSTI and more serious infections due to MRSA, but 
few comparative studies are available and no studies have 
  specifically evaluated the use of these agents in HIV-infected 
patients.
Conclusion
As the epidemiology of S. aureus (and MRSA specifically) 
continues to evolve, both colonization and infections with 
this organism have become increasingly common in the 
HIV-positive population. Behavioral, social, environmental, 
biologic, HIV host-specific risk factors, and, probably, a 
combination of all these play a significant role in explain-
ing the increased prevalence and incidence observed. The 
organism’s interactions with the immunocompromised host 
are complex, and involve defects in innate immunity.
Little data suggest that the treatment of MRSA infec-
tions in HIV-infected patients should be any different than 
the treatment in noninfected patients. Finally, whether 
improved HIV control will result in reduced risk of MRSA 
infections or recurrences remains to be proved in future 
studies.
Acknowledgments
This study was financially supported, in part, by the 
NIH Fogarty International Center (D43TW007124 and 
D43TW007124-06S1) and the Atlanta Clinical and Trans-
lational Science Institute (NIH/NCRR UL1RR025008) 
(Kempker).Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
82
Hidron et al
Disclosure
None of the authors in this manuscript have any conflicts of 
interest to disclose.
References
  1.  Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus 
bacteremia and recurrent staphylococcal infection in patients with 
acquired immunodeficiency syndrome and AIDS-related complex. 
Am J Med. 1988;85(2):172–176.
  2.  Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients 
with the acquired immune deficiency syndrome (AIDS) and AIDS-
related complex. Am J Med. 1987;82(5):900–906.
  3.  Onorato M, Borucki MJ, Baillargeon G, et al. Risk factors for coloniza-
tion or infection due to methicillin-resistant Staphylococcus aureus in 
HIV-positive patients: a retrospective case-control study. Infect Control 
Hosp Epidemiol. 1999;20(1):26–30.
  4.  Raviglione MC, Mariuz P, Pablos-Mendez A, Battan R, Ottuso P, 
Taranta A. High Staphylococcus aureus nasal carriage rate in patients 
with acquired immunodeficiency syndrome or AIDS-related complex. 
Am J Infect Control. 1990;18(2):64–69.
  5.  Weinke T, Schiller R, Fehrenbach FJ, Pohle HD. Association between 
Staphylococcus aureus nasopharyngeal colonization and septicemia in 
patients infected with the human immunodeficiency virus. Eur J Clin 
Microbiol Infect Dis. 1992;11(11):985–989.
  6.  Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: 
antimicrobial-resistant pathogens associated with healthcare-associated 
infections: annual summary of data reported to the National Healthcare 
Safety Network at the Centers for Disease Control and Prevention, 
2006–2007. Infect Control Hosp Epidemiol. 2008;29(11):996–1011.
  7.  Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, 
Wenzel RP. Emerging resistance among bacterial pathogens in the 
intensive care unit – a European and North American Surveillance 
study (2000–2002). Ann Clin Microbiol Antimicrob. 2004;3:14.
  8.  From the Centers for Disease Control and Prevention. Four pediatric 
deaths from community-acquired methicillin-resistant   Staphylococcus 
aureus – Minnesota and North Dakota, 1997–1999. JAMA. 1999; 
282(12):1123–1125.
  9.  From the Centers for Disease Control and Prevention. Methicillin-
resistant Staphylococcus aureus skin or soft tissue infections in a state 
prison – Mississippi, 2000. JAMA. 2002;287(2):181–182.
  10.  Outbreaks of community-associated methicillin-resistant   Staphylococcus 
aureus skin infections – Los Angeles County, California, 2002–2003. 
MMWR Morb Mortal Wkly Rep. 2003;52(5):88.
  11.  Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cas-
sette chromosome mec identified in community-acquired methicillin-
resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 
2002;46(4):1147–1152.
  12.  Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel 
type V staphylococcal cassette chromosome mec driven by a novel cas-
sette chromosome recombinase, ccrC. Antimicrob Agents Chemother. 
2004;48(7):2637–2651.
  13.  Vandenesch F, Naimi T, Enright MC, et al. Community-acquired 
methicillin-resistant Staphylococcus aureus carrying Panton-Val-
entine leukocidin genes: worldwide emergence. Emerg Infect Dis. 
2003;9(8):978–984.
  14.  Tristan A, Bes M, Meugnier H, et al. Global distribution of Panton-
Valentine leukocidin – positive methicillin-resistant Staphylococcus 
aureus, 2006. Emerg Infect Dis. 2007;13(4):594–600.
  15.  Smith JM, Cook GM. A decade of community MRSA in New Zealand. 
Epidemiol Infect. 2005;133(5):899–904.
  16.  King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, 
  Blumberg HM. Emergence of community-acquired methicillin-
resistant Staphylococcus aureus USA300 clone as the predominant 
cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5): 
309–317.
  17.  Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant 
S. aureus infections among patients in the emergency department. 
N Engl J Med. 2006;355(7):666–674.
  18.  CDC. Four pediatric deaths from community-acquired methicillin- 
resistant Staphylococcus aureus, Minnesota and North Dakota, 1997–
1999. MMWR Morb Mortal Wkly Rep. 1999;48:707–710.
  19.  CDC. Methicillin-Resistant Staphylococcus aureus Skin or Soft Tissue 
Infections in a State Prison, Mississippi, 2000. MMWR Morb Mortal 
Wkly Rep. 2001;50:919–922.
  20.  CDC. Methicillin-resistant Staphylococcus aureus infections among 
competitive sports participants: Colorado, Indiana, Pennsylvania, and 
Los Angeles County, 2000–2003. MMWR Morb Mortal Wkly Rep. 
2003;52:793–795.
  21.  Lindenmayer JM SS, O’Grady R, Carney JK. Methicillin-resistant 
Staphyloccus aureus in a high school wrestling team and the surround-
ing community. Arch Intern Med. 1998;158:895–899.
  22.  Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of commu-
nity- and health care-associated methicillin-resistant Staphylococcus 
aureus infection. JAMA. 2003;290(22):2976–2984.
  23.  Stacey AR, Endersby KE, Chan PC, Marples RR. An outbreak of 
methicillin-resistant Staphylococcus aureus infection in a rugby football 
team. Br J Sports Med. 1998;32(2):153–154.
  24.  Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant 
Staphylococcus aureus disease in three communities. N Engl J Med. 
2005;352(14):1436–1444.
  25.  DeLeo FR, Diep BA, Otto M. Host defense and pathogen-
esis in Staphylococcus aureus infections. Infect Dis Clin North Am. 
2009;23(1):17–34.
  26.  Harrison CJ. Innate immunity as a key element in host defense 
against methicillin-resistant Staphylococcus aureus. Minerva Pediatr. 
2009;61(5):503–514.
  27.  Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients 
with AIDS or AIDS-related complex: a comprehensive evaluation. 
J Infect Dis. 1988;158(6):1268–1276.
  28.  Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Impair-
ment of neutrophil chemotactic and bactericidal function in children 
infected with human immunodeficiency virus type 1 and partial reversal 
after in vitro exposure to granulocyte-macrophage colony-stimulating 
factor. J Pediatr. 1990;117(4):531–540.
  29.  Flo RW, Naess A, Nilsen A, Harthug S, Solberg CO. A longitudinal 
study of phagocyte function in HIV-infected patients. AIDS. 1994; 
8(6):771–777.
  30.  Elbim C, Prevot MH, Bouscarat F, et al. Polymorphonuclear neutro-
phils from human immunodeficiency virus-infected patients show 
enhanced activation, diminished fMLP-induced L-selectin shed-
ding, and an impaired oxidative burst after cytokine priming. Blood. 
1994;84(8):2759–2766.
  31.  Mastroianni CM, Lichtner M, Mengoni F, et al. Improvement in 
neutrophil and monocyte function during highly active antiret-
roviral treatment of HIV-1-infected patients. AIDS. 1999;13(8): 
883–890.
  32.  Pos O, Stevenhagen A, Meenhorst PL, Kroon FP, van Furth R. Impaired 
phagocytosis of Staphylococcus aureus by granulocytes and monocytes 
of AIDS patients. Clin Exp Immunol. 1992;88(1):23–28.
  33.  Dobmeyer TS, Raffel B, Dobmeyer JM, et al. Decreased function of 
monocytes and granulocytes during HIV-1 infection correlates with 
CD4 cell counts. Eur J Med Res. 1995;1(1):9–15.
  34.  Bandres JC, Trial J, Musher DM, Rossen RD. Increased phagocytosis 
and generation of reactive oxygen products by neutrophils and mono-
cytes of men with stage 1 human immunodeficiency virus infection. 
J Infect Dis. 1993;168(1):75–83.
  35.  Murphy PM, Lane HC, Fauci AS, Gallin JI. Impairment of neu-
trophil bactericidal capacity in patients with AIDS. J Infect Dis. 
1988;158(3):627–630.
  36.  Hayani KC, Verral SC, Pitrak DL. Impaired phagocyte oxidative capac-
ity in human immunodeficiency virus-infected children. J Infect Dis. 
1999;179(3):584–589.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
Methicillin-resistant Staphylococcus aureus in HIv-infected patients
  37.  Pitrak DL, Mullane KM, Bilek ML, Stevens P, Allen RC. Impaired 
phagocyte oxidative capacity in patients with human immunodeficiency 
virus infection. J Lab Clin Med. 1998;132(4):284–293.
  38.  Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial 
infection in patients with human immunodeficiency virus disease: 
the role of granulocyte colony-stimulating factor. Clin Infect Dis. 
2000;30(2):256–260.
  39.  Salmen S, Teran G, Borges L, et al. Increased Fas-mediated apoptosis in 
polymorphonuclear cells from HIV-infected patients. Clin Exp Immunol. 
2004;137(1):166–172.
  40.  Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P. Accelerated 
neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin 
Invest. 1996;98(12):2714–2719.
  41.  Salmen S, Montes H, Soyano A, Hernandez D, Berrueta L. Mechanisms 
of neutrophil death in human immunodeficiency virus-infected patients: 
role of reactive oxygen species, caspases and map kinase pathways. 
Clin Exp Immunol. 2007;150(3):539–545.
  42.  Hadad N, Levy R, Schlaeffer F, Riesenberg K. Direct effect of 
human immunodeficiency virus protease inhibitors on neutrophil 
function and apoptosis via calpain inhibition. Clin Vaccine Immunol. 
2007;14(11):1515–1521.
  43.  Noursadeghi M, Katz DR, Miller RF. HIV-1 infection of mononuclear 
phagocytic cells: the case for bacterial innate immune deficiency in 
AIDS. Lancet Infect Dis. 2006;6(12):794–804.
  44.  Pugliese A, Vidotto V, Beltramo T, Torre D. Phagocytic activity in 
human immunodeficiency virus type 1 infection. Clin Diagn Lab 
Immunol. 2005;12(8):889–895.
  45.  Torre D, Gennero L, Baccino FM, Speranza F, Biondi G, Pugliese A. 
Impaired macrophage phagocytosis of apoptotic neutrophils in patients 
with human immunodeficiency virus type 1 infection. Clin Diagn Lab 
Immunol. 2002;9:983–986.
  46.  Lane H, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. 
Abnormalities of B-cell activation and immunoregulation in patients 
with the acquired immunodeficiency syndrome. N Engl J Med. 
1983;309(8):453–458.
  47.  Pahwa SG QM, Lange M, Pahwa RN, Grieco MH. Defective 
B-lymphocyte function in homosexual men in relation to the 
acquired immunodeficiency syndrome. Ann Intern Med. 1984;101(6): 
757–763.
  48.  Hidron AI, Kourbatova EV , Halvosa JS, et al. Risk factors for colo-
nization with methicillin-resistant Staphylococcus aureus (MRSA) 
in patients admitted to an urban hospital: emergence of community-
associated MRSA nasal carriage. Clin Infect Dis. 2005;41(2): 
159–166.
  49.  Miller M, Cespedes C, Bhat M, Vavagiakis P, Klein RS, Lowy FD. 
Incidence and persistence of Staphylococcus aureus nasal colonization 
in a community sample of HIV-infected and -uninfected drug users. 
Clin Infect Dis. 2007;45(3):343–346.
  50.  Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, 
Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resis-
tance in the AIDS era. J Infect Dis. 1999;180(6):1809–1818.
  51.  McDonald LC, Lauderdale TL, Lo HJ, Tsai JJ, Hung CC. Coloniza-
tion of HIV-infected outpatients in Taiwan with methicillin-resistant 
and methicillin-susceptible Staphylococcus aureus. Int J STD AIDS. 
2003;14(7):473–477.
  52.  Miller M, Cespedes C, Vavagiakis P, Klein RS, Lowy FD. Staphylo-
coccus aureus colonization in a community sample of HIV-infected 
and HIV-uninfected drug users. Eur J Clin Microbiol Infect Dis. 
2003;22(8):463–469.
  53.  McNally LM, Jeena PM, Gajee K, et al. Lack of association between 
the nasopharyngeal carriage of Streptococcus pneumoniae and Staphy-
lococcus aureus in HIV-1-infected South African children. J Infect Dis. 
2006;194(3):385–390.
  54.  Shet A, Mathema B, Mediavilla JR, et al. Colonization and subsequent 
skin and soft tissue infection due to methicillin-resistant Staphylococcus 
aureus in a cohort of otherwise healthy adults infected with HIV type 1. 
J Infect Dis. 2009;200(1):88–93.
  55.  Padoveze MC, de Jesus Pedro R, Blum-Menezes D, Bratfich OJ, Moretti 
ML. Staphylococcus aureus nasal colonization in HIV outpatients: 
persistent or transient? Am J Infect Control. 2008;36(3):187–191.
  56.  Sissolak D, Geusau A, Heinze G, Witte W, Rotter ML. Risk factors for 
nasal carriage of Staphylococcus aureus in infectious disease patients, 
including patients infected with HIV , and molecular typing of colonizing 
strains. Eur J Clin Microbiol Infect Dis. 2002;21(2):88–96.
  57.  Shapiro M, Smith KJ, James WD, et al. Cutaneous microenvironment 
of human immunodeficiency virus (HIV)-seropositive and HIV-sero-
negative individuals, with special reference to Staphylococcus aureus 
colonization. J Clin Microbiol. 2000;38(9):3174–3178.
  58.  Szumowski JD, Wener KM, Gold HS, et al. Methicillin-resistant 
Staphylococcus aureus colonization, behavioral risk factors, and skin 
and soft-tissue infection at an ambulatory clinic serving a large popu-
lation of HIV-infected men who have sex with men. Clin Infect Dis. 
2009;49(1):118–121.
  59.  Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence 
of and risk factors for methicillin-resistant Staphylococcus aureus 
(MRSA) nasal colonization in HIV-infected ambulatory patients. 
J Acquir Immune Defic Syndr. 2008;48(5):567–571.
  60.  Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal 
colonization in HIV-seropositive and HIV-seronegative drug users. 
J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(4):301–306.
  61.  Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Hetero-
sexual transmission of community-associated methicillin-resistant 
  Staphylococcus aureus. Clin Infect Dis. 2007;44(3):410–413.
  62.  Miller M, Cook HA, Furuya EY, et al. Staphylococcus aureus in the com-
munity: colonization versus infection. PLoS One. 2009;4(8):e6708.
  63.  Nguyen MH, Kauffman CA, Goodman RP, et al. Nasal carriage of 
and infection with Staphylococcus aureus in HIV-infected patients. 
Ann Intern Med. 1999;130(3):221–225.
  64.  von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage 
as a source of Staphylococcus aureus bacteremia. Study Group. N Engl 
J Med. 2001;344(1):11–16.
  65.  Rieg G, Daar E, Witt M, Guerrero M, Miller L. Community-acquired 
methicillin-resistant Staphylococcus aureus colonization among 
HIV-infected men who have sex with men: a point prevalence survey. 
Presented at 12th Confecerence on Retroviruses and Opportunistic 
Infections, Boston, MA, Feb 22–25; abstract 8772005.
  66.  Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk 
factors for clinically significant methicillin-resistant Staphylococcus 
aureus infection in a cohort of HIV-infected adults. J Acquir Immune 
Defic Syndr. 2005;40(2):155–160.
  67.  Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis J, Gebo KA. 
The incidence of and risk factors for MRSA bacteraemia in an HIV-
infected cohort in the HAART era. HIV Med. 2008;9(10):858–862.
  68.  Skiest D, Brown K, Hester J, et al. Community-onset methicillin-
resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 
2006;7(6):361–368.
  69.  Crum-Cianflone N, Weekes J, Bavaro M. Recurrent community-associated 
methicillin-resistant Staphylococcus aureus infections among HIV-
infected persons: incidence and risk factors. AIDS Patient Care STDS. 
2009;23(7):499–502.
  70.  Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of   community- 
acquired methicillin-resistant Staphylococcus aureus infections among 
HIV-infected persons. Int J STD AIDS. 2007;18(8):521–526.
  71.  Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B.   Community- 
Associated Methicillin-Resistant Staphylococcus aureus and HIV: 
Intersecting Epidemics. Clin Infect Dis. 2010;50(7):979–987.
  72.  Srinivasan A, Seifried S, Zhu L, et al. Short communication: 
methicillin-resistant Staphylococcus aureus infections in children 
and young adults infected with HIV . AIDS Res Hum Retroviruses. 
2009;25(12):1219–1224.
  73.  Iyer S, Jones DH. Community-acquired methicillin-resistant 
Staphylococcus aureus skin infection: a retrospective analysis of clinical 
presentation and treatment of a local outbreak. J Am Acad Dermatol. 
2004;50(6):854–858.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
84
Hidron et al
  74.  Padoveze MC, Trabasso P, Branchini ML. Nosocomial infections 
among HIV-positive and HIV-negative patients in a Brazilian infec-
tious diseases unit. Am J Infect Control. 2002;30(6):346–350.
  75.  Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-
associated methicillin-resistant Staphylococcus aureus skin infections 
among HIV-positive men who have sex with men. Clin Infect Dis. 
2005;40(10):1529–1534.
  76.  Bar A, Hantschke D, Mirmohammadsadegh A, Hengge UR. Spectrum 
of bacterial isolates in HIV-positive patients with skin and soft tissue 
infections: emergence of methicillin-resistant Staphylococci. AIDS. 
2003;17(8):1253–1256.
  77.  Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-
resistant, community-associated, methicillin-resistant Staphylococcus 
aureus clone USA300 in men who have sex with men. Ann Intern 
Med. 2008;148(4):249–257.
  78.  Yang ES, Tan J, Eells S, Rieg G, Tagudar G, Miller LG. Body site colo-
nization in patients with community-associated methicillin-resistant 
Staphylococcus aureus and other types of S. aureus skin infections. 
Clin Microbiol Infect. 2010;16(5):425–431.
  79.  Ramsetty SK, Stuart LL, Blake RT, Parsons CH, Salgado CD. Risks for 
methicillin-resistant Staphylococcus aureus colonization or infection 
among patients with HIV infection. HIV Med. 2010;11(6):389–394.
  80.  Smith NP, Nelson MR, Azadian B, Gazzard BG. An outbreak of 
methicillin-resistant Staphylococcus aureus (MRSA) infection in 
HIV-seropositive persons. Int J STD AIDS. 1998;9(12):726–730.
  81.  Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep 
BA. Recurrence of skin and soft tissue infection caused by methicillin-
resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir 
Immune Defic Syndr. 2008;49(2):231–233.
  82.  Drapeau CM, Angeletti C, Festa A, Petrosillo N. Role of previous 
hospitalization in clinically-significant MRSA infection among HIV-
infected inpatients: results of a case-control study. BMC Infect Dis. 
2007;7:36.
  83.  Krucke GW, Grimes DE, Grimes RM, Dang TD. Antibiotic Resistance 
in Staphylococcus aureus-containning cutaneous abscesses of patients 
with HIV . Am J Emerg Med. 2009;27:344–347.
  84.  Trinh TT, Short WR, Mermel LA. Community-associated methicillin-
resistant Staphylococcus aureus skin and soft-tissue infection in 
HIV-infected patients. J Int Assoc Physicians AIDS Care (Chic Ill). 
2009;8(3):176–180.
  85.  Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-
Valentine leukocidin-producing Staphylococcus aureus in pri-
mary skin infections and pneumonia. Clin Infect Dis. 1999;29(5): 
1128–1132.
  86.  Crum-Cianflone N. Increased Risk for MRSA Skin and Soft Tissue 
Infections Among HIV-Infected Persons. Available from http://www.
medscape.com. Accessed Jan 27, 2010.
  87.  Olsen RJ, Burns KM, Chen L, Kreiswirth BN, Musser JM. Severe 
necrotizing fasciitis in a human immunodeficiency virus-positive 
patient caused by methicillin-resistant Staphylococcus aureus. J Clin 
Microbiol. 2008;46(3):1144–1147.
  88.  Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis 
caused by community-associated methicillin-resistant Staphylococcus 
aureus in Los Angeles. N Engl J Med. 2005;352(14):1445–1453.
  89.  Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presenta-
tion of community-acquired MRSA pneumonia. Chest. Epub   
2010 Feb 19.
  90.  Gebo KA, Burkey MD, Lucas GM, Moore RD, Wilson LE. Incidence 
of, risk factors for, clinical presentation, and 1-year outcomes of 
infective endocarditis in an urban HIV cohort. J Acquir Immune Defic 
Syndr. 2006;43(4):426–432.
  91.  Durao D, Fernandes AP, Marum S, Marcelino P, Mourao L. Cardiac 
tamponade secondary to methicillin-resistant Staphylococcus aureus 
pericarditis. Rev Port Cardiol. 2008;27(7–8):953–958.
  92.  Pedro-Botet ML, Modol JM, Valles X, et al. Changes in bloodstream 
infections in HIV-positive patients in a university hospital in Spain 
(1995–1997). Int J Infect Dis. 2002;6(1):17–22.
  93.  Krumholz HM, Sande MA, Lo B. Community-acquired bacteremia 
in patients with acquired immunodeficiency syndrome: clinical pre-
sentation, bacteriology, and outcome. Am J Med. 1989;86(6 Pt 2): 
776–779.
  94.  Stroud L, Srivastava P, Culver D, et al. Nosocomial infections 
in HIV-infected patients: preliminary results from a multicenter 
surveillance system (1989–1995). Infect Control Hosp Epidemiol. 
1997;18(7):479–485.
  95.  Tumbarello M, de Gaetano Donati K, Tacconelli E, et al. Risk factors 
and predictors of mortality of methicillin-resistant Staphylococcus 
aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob 
Chemother. 2002;50(3):375–382.
  96.  Senthilkumar A, Kumar S, Sheagren JN. Increased incidence of 
Staphylococcus aureus bacteremia in hospitalized patients with 
acquired immunodeficiency syndrome. Clin Infect Dis. 2001; 
33(8):1412–1416.
  97.  Uche A, Forrest G. Staphylococcus aureus bacteremia in HIV-infected 
patients in the HAART era. Presented at 44th Annual Meeting of the 
Infectious Diseases Society of America (IDSA). Boston, MA, October 
12–15;2006.
  98.  Seybold U, Kourbatova EV , Johnson JG, et al. Emergence of com-
munity-associated methicillin-resistant Staphylococcus aureus USA 
300 genotype as a major cause of health care-associated blood stream 
infections. Clin Infect Dis. 2006;42(5):647–656.
  99.  Laupland KB, Ross T, Gregson DB. Staphylococcus aureus blood-
stream infections: risk factors, outcomes, and the influence of 
methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis. 
2008;198(3):336–343.
  100.  Kreisel K, Boyd K, Langenberg P, Roghmann MC. Risk factors 
for recurrence in patients with Staphylococcus aureus infections 
complicated by bacteremia. Diagn Microbiol Infect Dis. 2006; 
55(3):179–184.
  101.  Perovic O, Koornhof H, Black V, Moodley I, Duse A, Galpin J. 
Staphylococcus aureus bacteraemia at two academic hospitals in 
Johannesburg. S Afr Med J. 2006;96(8):714–717.
  102.  Nahass RG, Weinstein MP, Bartels J, Gocke DJ. Infective endo-
carditis in intravenous drug users: a comparison of human immuno-
deficiency virus type 1-negative and -positive patients. J Infect Dis. 
1990;162(4):967–970.
  103.  Ribera E, Miro JM, Cortes E, et al. Influence of human immuno-
deficiency virus 1 infection and degree of immunosuppression in 
the clinical characteristics and outcome of infective endocarditis in 
intravenous drug users. Arch Intern Med. 1998;158(18):2043–2050.
  104.  Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A, Fraile J, 
de Gorgolas M. Endocarditis caused by Staphylococcus aureus: a reap-
praisal of the epidemiologic, clinical, and pathologic manifestations 
with analysis of factors determining outcome. Medicine (Baltimore). 
2009;88(1):1–22.
  105.  Tsai HC, Chao PJ, Sy CL, et al. Community-associated methicillin-
resistant Staphylococcus aureus infective endocarditis with Panton-
Valentine leukocidin gene in an injection drug user with HIV infection. 
Intern Med. 2008;47(16):1485–1489.
  106.  Franzetti F, Grassini A, Piazza M, et al. Nosocomial bacterial pneu-
monia in HIV-infected patients: risk factors for adverse outcome 
and implications for rational empiric antibiotic therapy. Infection. 
2006;34(1):9–16.
  107.  Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of 
community-acquired meticillin-resistant Staphylococcus aureus strain 
USA300 as a cause of necrotising community-onset pneumonia. 
Lancet Infect Dis. 2009;9(6):384–392.
  108.  Shastry L, Rahimian J, Lascher S. Community-associated methicillin-
resistant Staphylococcus aureus skin and soft tissue infections in 
men who have sex with men in New York City. Arch Intern Med. 
2007;167(8):854–857.
  109.  Fergie JE, Purcell K. Community-acquired methicillin-resistant 
Staphylococcus aureus infections in south Texas children. Pediatr 
Infect Dis J. 2001;20(9):860–863.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
85
Methicillin-resistant Staphylococcus aureus in HIv-infected patients
  110.  Lee MC, Rios AM, Aten MF, et al. Management and outcome of 
children with skin and soft tissue abscesses caused by community-
acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect 
Dis J. 2004;23(2):123–127.
  111.  Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset 
methicillin-resistant Staphylococcus aureus skin and soft-tissue infec-
tions: impact of antimicrobial therapy on outcome. Clin Infect Dis. 
2007;44(6):777–784.
  112.  Moellering RC Jr. Current treatment options for community-acquired 
methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 
2008;46(7):1032–1037.
  113.  Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment 
of uncomplicated skin infections in the era of community-associated 
methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 
2007;44(6):785–787.
  114.  Ahuja D, Albrecht H. HIV and community-acquired MRSA. AIDS 
Clin Care. 2009;21(3):21–23.
  115.  Kaka AS, Rueda AM, Shelburne SA III, Hulten K, Hamill RJ, 
Musher DM. Bactericidal activity of orally available agents against 
methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 
2006;58(3):680–683.
  116.  Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethox-
azole compared with vancomycin for the treatment of Staphylococcus 
aureus infection. Ann Intern Med. 1992;117(5):390–398.
  117.  Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and 
outcomes of infections by methicillin-resistant Staphylococcus 
aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007; 
51(2):423–428.
  118.  Alonso R, Padilla B, Sanchez-Carrillo C, Munoz P, Rodriguez-
Creixems M, Bouza E. Outbreak among HIV-infected patients of 
Staphylococcus aureus resistant to cotrimoxazole and methicillin. 
Infect Control Hosp Epidemiol. 1997;18(9):617–621.
  119.  Gordon RJ, Quagliarello B, Cespedes C, et al. A molecular epi-
demiological analysis of 2 Staphylococcus aureus clonal types 
colonizing and infecting patients with AIDS. Clin Infect Dis. 
2005;40(7):1028–1036.
  120.  Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 
Impact of antibiotics on expression of virulence-associated exotoxin 
genes in methicillin-sensitive and methicillin-resistant Staphylococcus 
aureus. J Infect Dis. 2007;195(2):202–211.
  121.  Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on 
Staphylococcus aureus producing Panton-Valentine leukocidin. 
Antimicrob Agents Chemother. 2007;51(4):1515–1519.
  122.  Daum RS. Clinical practice. Skin and soft-tissue infections caused 
by methicillin-resistant Staphylococcus aureus. N Engl J Med. 
2007;357(4):380–390.
  123.  Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin 
treatment of methicillin-resistant Staphylococcus aureus express-
ing inducible clindamycin resistance in vitro. Clin Infect Dis. 
2003;37(9):1257–1260.
  124.  Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting 
tetracyclines for methicillin-resistant Staphylococcus aureus infec-
tions: case series and review of the literature. Clin Infect Dis. 
2005;40(10):1429–1434.
  125.  Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-
  Remington F. Roles of 34 virulence genes in the evolution of 
hospital- and community-associated strains of methicillin-resistant 
Staphylococcus aureus. J Infect Dis. 2006;193(11):1495–1503.
  126.  Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of 
clindamycin and tetracycline resistance in methicillin-resistant 
Staphylococcus aureus pulsed-field type USA300 isolates collected 
at a Boston ambulatory health center. J Clin Microbiol. 2007;45(4): 
1350–1352.
  127.  Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. 
  Linezolid versus vancomycin in treatment of complicated skin and 
soft tissue infections. Antimicrob Agents Chemother. 2005;49(6): 
2260–2266.
  128.  Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic 
patients: a randomized, multicenter, open-label trial of linezolid 
versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 
2004;38(1):17–24.
  129.  Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a 
clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277): 
207–208.
  130.  Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. 
J Infect. 2009;59 Suppl 1:S59–S74.
  131.  Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral 
  neuropathy associated with prolonged use of linezolid. Lancet Infect 
Dis. 2004;4(8):528–531.
  132.  Ferry T, Ponceau B, Simon M, et al. Possibly linezolid-induced 
peripheral and central neurotoxicity: report of four cases. Infection. 
2005;33(3):151–154.
  133.  Stevens DL. The role of vancomycin in the treatment paradigm. Clin 
Infect Dis. 2006;42 Suppl 1:S51–S57.
  134.  Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese 
hospitals of strains of Staphylococcus aureus heterogeneously resistant 
to vancomycin. Lancet. 1997;350(9092):1670–1673.
  135.  Tenover FC. Rapid detection and identification of bacterial pathogens 
using novel molecular technologies: infection control and beyond. Clin 
Infect Dis. 2007;44(3):418–423.
  136.  Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among 
methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 
2008;46 Suppl 5:S360–S367.
  137.  Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. 
Clinical features associated with bacteremia due to heterogeneous 
vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 
2004;38(3):448–451.
  138.  Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, 
Moellering RC Jr. Accessory gene regulator group II polymorphism 
in methicillin-resistant Staphylococcus aureus is predictive of failure 
of vancomycin therapy. Clin Infect Dis. 2004;38(12):1700–1705.
  139.  Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-
dose vancomycin therapy for methicillin-resistant Staphylococcus 
aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 
166(19):2138–2144.
  140.  Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. 
Linezolid versus vancomycin for the treatment of methicillin-
resistant Staphylococcus aureus infections. Clin Infect Dis. 
2002;34(11):1481–1490.
  141.  Skrupky LP, Micek ST, Kollef MH. Optimizing therapy for MRSA 
pneumonia. Semin Respir Crit Care Med. 2007;28(6):615–623.
  142.  Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for 
serious infections caused by methicillin-resistant Staphylococcus 
aureus with reduced vancomycin susceptibility. Clin Infect Dis. 
2004;38(4):521–528.
  143.  Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicil-
lin-resistant Staphylococcus aureus: treatment failure with linezolid. 
Clin Infect Dis. 2002;35(8):1018–1020.
  144.  Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in 
a patient with low linezolid levels. Clin Infect Dis. 2003;36(5): 
675–676.
  145.  Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety 
and efficacy of daptomycin for the treatment of complicated skin and 
skin-structure infections. Clin Infect Dis. 2004;38(12):1673–1681.
  146.  Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus 
standard therapy for bacteremia and endocarditis caused by Staphy-
lococcus aureus. N Engl J Med. 2006;355(7):653–665.
  147.  Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, 
  Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus 
with reduced vancomycin susceptibility is independent of alterations 
in MprF. Antimicrob Agents Chemother. 2007;51(6):2223–2225.
  148.  Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of 
daptomycin by pulmonary surfactant: in vitro modeling and clinical 
impact. J Infect Dis. 2005;191(12):2149–2152.Infection and Drug Resistance
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance is an international, peer-reviewed open-
access journal that focuses on the optimal treatment of infection (bacte-
rial, fungal and viral) and the development and institution of preventive 
strategies to minimize the development and spread of resistance. The 
journal is specifically concerned with the epidemiology of antibiotic 
resistance and the mechanisms of resistance development and diffusion 
in both hospitals and the community. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
86
Hidron et al
  149.  Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, 
Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin 
Infect Dis. 2006;42(12):e108–e110.
  150.  Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecy-
cline in treatment of skin and skin structure infections: results of a 
double-blind phase 3 comparison study with vancomycin-aztreonam. 
Antimicrob Agents Chemother. 2005;49(11):4658–4666.
  151.  Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 
2006;43(4):518–524.
  152.  Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced 
Pancreatitis. J Clin Gastroenterol. 2009;43(1):93.
  153.  Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecycline-
induced acute pancreatitis: case report and literature review. Int J 
Antimicrob Agents. 2009;34(5):486–489.
  154.  Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, 
Talbot GH. Treatment of methicillin-resistant staphylococcus aureus 
infections with quinupristin-dalfopristin in patients intolerant of or 
failing prior therapy. For the Synercid Emergency-Use Study Group. 
J Antimicrob Chemother. 2000;46(5):775–784.
  155.  Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of 
  quinupristin/dalfopristin for treatment of invasive Gram-positive infec-
tions in pediatric patients. Pediatr Infect Dis J. 2002;21(10):950–956.
  156.  Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias 
related to quinupristin-dalfopristin administration. Clin Infect Dis. 
2001;32(4):e83–e86.
  157.  Seybold U, Supthut-Schroder B, Draenert R, Hogardt M, Bogner JR. 
Prevalence and risk factors of nasal colonization with Staphylococcus 
aureus – association with HIV infection in older patients. Scand J 
Infect Dis. 2009;41(1):63–66.
  158.  Madariaga MG, Ullrich F, Swindells S. Low prevalence of 
  community-acquired methicillin-resistant Staphylococcus aureus 
colonization and apparent lack of correlation with sexual behav-
ior among HIV-infected patients in Nebraska. Clin Infect Dis. 
2009;48(10):1485–1487.
  159.  Lu P SL, Chen T, Feng M, Chen Y. Risk factors for methicillin-resistant 
Staphylococcus aureus (MRSA) carriage among HIV-infected cohort 
in an MRSA prevalence area. XVI International AIDS Conference, 
Toronto, Canada, Aug 13–18, 2006; abstract CDB02792006.
  160.  Villacian JS, Barkham T, Earnest A, Paton NI. Prevalence of and 
risk factors for nasal colonization with Staphylococcus aureus among 
human immunodeficiency virus-positive outpatients in Singapore. 
Infect Control Hosp Epidemiol. 2004;25(5):438–440.
  161.  Padoveze MC, Tresoldi AT, von Nowakonski A, Aoki FH, 
Branchini ML. Nasal MRSA colonization of AIDS Patients cared for in 
a Brazilian university hospital. Infect Control Hosp Epidemiol. 2001; 
22(12):783–785.
  162.  Chacko J, Kuruvila M, Bhat GK. Factors affecting the nasal car-
riage of methicillin-resistant Staphylococcus aureus in human 
immunodeficiency virus-infected patients. Indian J Med Microbiol. 
2009;27(2):146–148.